SyMap

SyMap is an internationally leading company that focuses on the research, development, and application of breakthrough innovative minimally invasive interventional technologies for treating major diseases in the cardiovascular and respiratory fields. It has a rich product pipeline at various stages of development: Its internationally first-of-its-kind/global leader, the renal nerve mapping/selective ablation system SyMapCath®™/SymPioneer®™ for treating hypertension, is expected to gain NMPA approval for market launch in 2023 through the special approval process for innovative medical devices. Its bronchoscopy-based radiofrequency ablation system Elation®™ for treating severe asthma is the only product in this field to have been approved by the NMPA for entry into the special approval process for innovative medical devices, with expectations to be approved for market release in 2024. The world's first Precisely Controlled, Hypertonic Solution Assisted RF System ("Zedan" system) developed for treating early-stage lung cancer via bronchoscopy has completed its First-in-Human (FIH) clinical trial in Australia, and preliminary efficacy and safety results of the "Zedan" system in treating early-stage pulmonary tumors were recently presented at the 32nd European Respiratory Society (ERS) Annual Congress. Relying on a professional talent team with internationally advanced standards, SyMap collaborates with world-renowned clinical scientists and researchers using disruptive minimally invasive interventional treatment technologies. "Leveraging China to impact the world," SyMap aims to serve global patients with China-originated disruptive products and has become an international frontrunner in active minimally invasive interventional methods for treating major diseases in the cardiovascular and respiratory fields.